YOLFTbeta
Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

NBIX · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

167.40USD-2.00 (-1.18%)

Price History

Full chart

Market Stats

Previous Close169.40
Open169.96
Day Range164.65 – 171.16
52-Week Range122.14 – 186.12
Volume1.38M
Market Cap14.77B
P/E (TTM)21.44
Forward P/E14.88
EPS6.78
Dividend Yield0.00%
Beta0.33
50-Day Avg146.63
200-Day Avg147.38

About

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Kyle W. Gano Ph.D.
  • Employees2.50K
  • Headquarters6027 Edgewood Bend Court, San Diego, CA, United States, 92130, USA
  • Websitehttps://www.neurocrine.com

Leadership

  • Mr. Kyle W. Gano Ph.D.President, CEO & Director · b. 1973
  • Mr. Matthew C. Abernethy CPAChief Financial Officer · b. 1980
  • Dr. Jude Onyia Ph.D.Chief Scientific Officer · b. 1964
  • Mr. Eric S. BenevichChief Commercial Officer · b. 1965
  • Dr. Eiry Wyn Roberts M.D.Chief Medical Officer · b. 1964
  • Dr. Wylie W. Vale Ph.D.Co-Founder · b. 1942
  • Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder of Neurocrine · b. 1948
  • Mr. Aaron VosburghSenior Vice President of Finance & Accounting
  • Mr. Lewis ChoiChief Information Officer
  • Mr. Todd TushlaVice President of Investor Relations

Financials

Income Statement

Currency: USD1996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue19.20M26.10M16.00M16.80M14.59M41.24M18.05M139.08M85.18M123.89M39.23M1.22M3.98M2.95M33.50M77.41M53.14M2.92M019.77M15.00M161.63M451.24M788.10M1.05B1.13B1.49B1.89B2.36B2.86B
Growth (%)-+35.94%-38.70%+5.00%-13.17%+182.71%-56.25%+670.73%-38.76%+45.45%-68.33%-96.88%+224.75%-25.71%+1034.47%+131.08%-31.36%-94.51%-100.00%--24.12%+977.51%+179.19%+74.65%+32.71%+8.38%+31.34%+26.76%+24.81%+21.45%
Cost of Revenue-1.00M-1.30M-1.70M-2.10M-2.20M22.25M118.56M194.17M130.43M138.87M132.49M103.16M65.87M44.88M42.99M41.72M11.60M13.80M14.40M33.80M35.90M1.25M4.89M7.40M10.10M14.30M23.20M39.70M34.00M52.10M
Gross Profit20.20M27.40M17.70M18.90M16.79M41.24M18.05M139.08M85.18M123.89M39.23M1.22M3.98M2.95M33.50M77.41M41.54M-10.88M-14.40M19.77M15.00M160.37M446.35M780.70M1.04B1.12B1.47B1.85B2.32B2.81B
Gross Margin105.21%104.98%110.63%112.50%115.07%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%78.17%-372.76%-100.00%100.00%99.22%98.92%99.06%99.03%98.74%98.44%97.90%98.56%98.18%
Operating Expense17.30M26.90M30.10M38.80M52.39M85.12M121.66M197.87M137.51M148.96M152.55M213.47M91.27M56.62M47.22M43.49M40.09M38.80M50.01M113.97M162.37M291.73M409.46M708.40M872.80M1.02B1.22B1.60B1.75B2.19B
Operating Income2.90M500.00K-12.40M-19.90M-35.60M-43.88M-103.61M-58.79M-52.33M-25.07M-113.32M-212.24M-87.30M-53.67M-13.72M33.92M1.45M-49.68M-64.41M-94.20M-147.37M-131.36M36.90M72.30M163.00M102.50M249.00M250.90M570.50M619.10M
Operating Margin15.10%1.92%-77.50%-118.45%-244.04%-106.40%-574.20%-42.27%-61.44%-20.24%-288.82%-17340.03%-2196.18%-1817.47%-40.96%43.82%2.72%-1701.88%--476.51%-982.48%-81.27%8.18%9.17%15.58%9.04%16.73%13.30%24.22%21.64%
EBITDA500.00K1.80M-10.70M-17.80M-33.40M-41.23M-100.52M-55.09M-45.25M-14.98M-102.75M-202.84M-73.98M-47.93M-12.29M34.62M2.10M-49.01M-63.58M-87.92M-139.64M-120.62M40.92M85.90M148.10M138.10M264.60M416.10M639.70M666.60M
EBITDA Margin2.60%6.90%-66.88%-105.95%-228.98%-99.97%-557.04%-39.61%-53.13%-12.09%-261.89%-16571.73%-1861.08%-1623.23%-36.67%44.72%3.96%-1678.90%--444.74%-930.91%-74.63%9.07%10.90%14.16%12.18%17.77%22.05%27.16%23.30%
Net Income5.90M5.10M-20.00M-16.80M-28.81M-36.91M-94.54M-30.26M-45.77M-22.19M-107.20M-207.30M-88.61M-51.04M-7.97M37.57M5.03M-46.09M-60.54M-88.93M-141.09M-142.54M21.11M37.00M407.30M89.60M154.50M249.70M341.30M478.60M
Net Income Margin30.73%19.54%-125.00%-100.00%-197.48%-89.50%-523.89%-21.75%-53.74%-17.91%-273.25%-16936.19%-2229.26%-1728.34%-23.78%48.53%9.46%-1578.97%--449.84%-940.60%-88.19%4.68%4.69%38.94%7.90%10.38%13.23%14.49%16.73%
R&D12.60M19.90M21.80M29.20M40.23M74.27M108.94M177.27M115.07M106.63M97.68M81.98M55.54M33.72M31.15M30.95M37.16M39.25M46.42M81.49M94.29M91.83M160.52M200.00M275.00M328.10M463.80M565.00M731.10M1.02B
R&D as % of Total Revenue65.63%76.25%136.25%173.81%275.75%180.08%603.71%127.46%135.09%86.07%248.96%6698.12%1397.33%1141.96%92.99%39.98%69.93%1344.57%-412.22%628.61%56.81%35.57%25.38%26.29%28.95%31.15%29.94%31.04%35.51%
Interest Expense000000485.00K516.00K1.96M4.16M3.72M3.92M7.03M7.03M7.03M00000019.52M30.53M32.00M32.80M25.80M7.10M4.60M126.60M-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%2.69%0.37%2.30%3.36%9.49%320.51%176.73%237.89%20.97%0.00%0.00%0.00%-0.00%0.00%12.08%6.77%4.06%3.14%2.28%0.48%0.24%5.38%-

Balance Sheet

Currency: USD1996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets78.00M91.90M80.50M109.20M185.96M346.35M266.54M554.96M519.22M483.12M389.68M276.65M118.18M70.82M144.42M138.37M195.98M154.68M243.03M474.79M365.09M817.59M993.15M1.31B1.73B2.07B2.37B3.25B3.72B4.63B
Total Liabilities5.20M8.70M8.50M12.80M22.75M35.96M42.28M163.84M125.39M93.02M74.96M157.96M81.41M66.86M125.08M78.29M41.61M34.27M34.33M50.33M50.21M445.45M512.39M669.10M608.50M698.50M660.90M1.02B1.13B1.38B
Total Equity72.80M83.20M72.00M96.40M163.21M310.39M224.25M391.12M393.83M390.10M314.72M118.70M36.77M3.95M19.34M60.08M154.37M120.41M208.70M424.45M314.88M372.14M480.76M636.90M1.13B1.37B1.71B2.23B2.59B3.25B
Cash11.30M15.80M11.70M21.30M21.08M163.89M44.31M105.85M61.03M49.95M80.98M99.66M68.47M37.33M54.05M50.11M63.75M44.79M31.01M74.19M83.27M254.71M141.71M112.28M187.10M340.80M262.90M251.10M233.00M713.00M
Total Debt1.60M1.60M3.00M3.10M3.87M5.69M7.93M36.43M66.13M59.40M53.64M1.49M15.40M11.53M-------407.99M450.84M817.61M412.30M440.40M262.90M428.40M455.10M415.30M
Net Debt-9.70M-14.20M-8.70M-18.20M-17.21M-158.20M-36.38M-69.42M5.10M9.46M-27.34M-98.18M-53.07M-25.80M-54.05M-50.11M-63.75M-44.79M-31.01M-74.19M-83.27M114.91M246.78M383.22M225.20M99.60M169.40M177.30M222.10M-297.70M

Cash Flow

Currency: USD1996-12-311997-12-311998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.70M11.00M-10.70M-10.30M-18.64M-21.86M-79.36M37.13M-99.99M-30.79M-99.33M-59.33M-74.17M-53.09M49.94M-698.00K-35.29M-29.61M-47.14M-38.00M-106.18M-94.33M101.40M147.00M228.50M256.50M339.40M389.90M595.40M782.70M
Investing Cash Flow--7.20M4.70M-21.20M-75.67M-16.64M-46.02M-186.65M18.47M9.38M120.28M20.84M44.42M12.06M-54.70M-3.53M-34.76M5.34M-105.37M-195.81M112.95M-251.25M-242.90M-211.10M4.10M-130.20M-177.10M-467.10M-126.80M-264.40M
Financing Cash Flow46.80M700.00K1.90M41.00M94.13M181.30M5.81M211.06M36.69M10.33M10.09M57.18M-1.45M9.90M21.48M286.00K83.70M5.30M138.73M276.99M2.39M516.65M29.50M32.40M-157.80M27.40M-234.30M65.30M-486.70M-38.30M
Capital Expenditure1.60M6.40M3.70M2.10M2.44M3.81M5.30M50.44M53.15M7.24M3.11M624.00K1.32M35.00K315.00K750.00K971.00K545.00K1.61M1.93M4.11M6.94M24.80M14.70M10.90M23.40M16.50M28.30M38.20M34.00M
Free Cash Flow5.10M4.60M-14.40M-12.40M-21.09M-25.66M-84.67M-13.31M-153.13M-38.03M-102.44M-59.96M-75.49M-53.13M49.63M-1.45M-36.27M-30.15M-48.75M-39.93M-110.29M-101.27M76.60M132.30M217.60M233.10M322.90M361.60M557.20M748.70M
Dividends Paid---------------0000000--------
FCF to OCF76.12%41.82%134.58%120.39%113.09%117.41%106.68%-35.85%153.15%123.49%103.13%101.05%101.78%100.07%99.37%207.45%102.75%101.84%103.42%105.09%103.87%107.36%75.54%90.00%95.23%90.88%95.14%92.74%93.58%95.66%
Dividend Paid to FCF---------------0.00%0.00%0.00%0.00%0.00%0.00%0.00%--------

Earnings

Report DateJul 31, 1996Nov 4, 1996Feb 3, 1997Apr 24, 1997Jul 31, 1997Oct 31, 1997Feb 17, 1998May 4, 1998Aug 4, 1998Nov 2, 1998Mar 5, 1999May 5, 1999Aug 3, 1999Nov 1, 1999Feb 14, 2000Apr 27, 2000Jul 28, 2000Nov 2, 2000Jan 30, 2001Apr 30, 2001Jul 31, 2001Nov 1, 2001Feb 5, 2002Apr 29, 2002Jul 30, 2002Oct 30, 2002Feb 3, 2003Apr 29, 2003Jul 24, 2003Nov 3, 2003Jan 29, 2004May 3, 2004Jul 28, 2004Nov 1, 2004Feb 10, 2005Apr 28, 2005Aug 3, 2005Oct 24, 2005Jan 23, 2006Apr 24, 2006Jul 17, 2006Nov 2, 2006Feb 1, 2007May 3, 2007Jul 31, 2007Nov 1, 2007Feb 5, 2008Apr 30, 2008Jul 30, 2008Oct 28, 2008Feb 3, 2009May 5, 2009Jul 29, 2009Oct 28, 2009Feb 3, 2010Apr 28, 2010Jul 28, 2010Oct 28, 2010Feb 10, 2011May 3, 2011Jul 28, 2011Oct 31, 2011Feb 8, 2012May 2, 2012Jul 31, 2012Oct 31, 2012Feb 8, 2013May 2, 2013Jul 25, 2013Oct 29, 2013Feb 6, 2014Apr 30, 2014Aug 6, 2014Nov 3, 2014Feb 9, 2015Apr 30, 2015Jul 29, 2015Oct 29, 2015Feb 11, 2016May 5, 2016Aug 3, 2016Nov 2, 2016Feb 14, 2017May 9, 2017Aug 3, 2017Nov 1, 2017Feb 13, 2018Apr 30, 2018Jul 31, 2018Nov 5, 2018Feb 5, 2019Apr 29, 2019Jul 29, 2019Nov 4, 2019Feb 4, 2020May 6, 2020Aug 3, 2020Nov 9, 2020Feb 4, 2021May 5, 2021Aug 3, 2021Nov 1, 2021Feb 11, 2022May 4, 2022Aug 4, 2022Nov 1, 2022Feb 6, 2023May 3, 2023Aug 1, 2023Oct 31, 2023Feb 7, 2024May 1, 2024Aug 1, 2024Oct 30, 2024Feb 6, 2025May 5, 2025Jul 30, 2025Oct 28, 2025Feb 11, 2026May 5, 2026Jul 30, 2026Oct 27, 2026Nov 2, 2026
EPS Estimate0.040.030.210.12-0.020.05-0.01-0.04-0.17-0.190.00-0.09-0.22-0.23-0.25-0.37-0.17-0.13-0.41-0.56-0.62-0.30-0.48-0.66-0.67-0.81-0.85-0.40-0.38-0.38-0.12-0.39-0.28-0.39-0.40-0.64-0.240.51-0.70-0.71-0.73-0.89-0.77-0.67-0.72-0.78-0.85-0.54-0.52-0.51-0.51-0.39-0.39-0.35-0.28-0.24-0.160.050.050.060.040.200.02-0.01-0.03-0.04-0.07-0.18-0.19-0.20-0.17-0.19-0.18-0.20-0.24-0.30-0.29-0.32-0.35-0.31-0.49-0.57-0.55-0.72-0.65-0.530.18-0.30-0.180.490.19-0.890.250.640.750.641.021.250.900.720.760.800.880.590.891.121.440.741.121.331.511.291.531.821.931.091.502.072.301.701.881.991.95
EPS Actual0.11-0.020.240.230.010.060.00-0.07-0.14-0.22-0.18-0.22-0.24-0.23-0.19-0.28-0.24-0.37-0.29-0.45-0.520.09-0.53-0.52-0.65-0.66-1.27-0.43-0.33-0.310.09-0.35-0.31-0.05-0.57-0.51-0.150.68-0.65-0.69-0.73-1.03-0.39-0.68-0.69-0.72-0.89-0.55-0.55-0.46-0.75-0.38-0.37-0.21-0.22-0.19-0.090.060.070.050.030.560.02-0.01-0.01-0.050.14-0.18-0.18-0.17-0.16-0.17-0.18-0.21-0.26-0.01-0.28-0.40-0.34-0.22-0.46-0.43-0.51-0.90-0.68-0.130.07-0.47-0.070.520.19-1.120.540.560.350.821.420.970.910.490.630.640.040.300.841.081.24-0.511.251.541.541.201.631.811.690.701.652.171.881.942.36-2.78
Surprise175.00%-166.67%14.29%91.67%150.00%20.00%100.00%-75.00%17.65%-15.79%--144.44%-9.09%0.00%24.00%24.32%-41.18%-184.62%29.27%19.64%16.13%130.00%-10.42%21.21%2.99%18.52%-49.41%-7.50%13.16%18.42%175.00%10.26%-10.71%87.18%-42.50%20.31%37.50%33.33%7.14%2.82%0.00%-15.73%49.35%-1.49%4.17%7.69%-4.71%-1.85%-5.77%9.80%-47.06%2.56%5.13%40.00%21.43%20.83%43.75%20.00%40.00%-16.67%-25.00%180.00%0.00%0.00%66.67%-25.00%300.00%0.00%5.26%15.00%5.88%10.53%0.00%-5.00%-8.33%96.67%3.45%-25.00%2.86%29.03%6.12%24.56%7.27%-25.00%-4.62%75.47%-61.11%-56.67%61.11%6.12%0.00%-25.84%116.00%-12.50%-53.33%28.13%39.22%-22.40%1.11%-31.94%-17.11%-20.00%-95.45%-49.15%-5.62%-3.57%-13.89%-168.92%11.61%15.79%1.99%-6.98%6.54%-0.55%-12.44%-35.78%10.00%4.83%-18.26%14.12%25.53%-42.56%
Timing---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----------Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours

Key Statistics & Ratios

Market Cap14.77B
Enterprise Value14.86B
Trailing P/E21.44
Forward P/E14.88
PEG Ratio0.30
Price / Sales4.38
Price / Book4.02
EPS6.78
Book Value36.35
Revenue (TTM)3.37B
Gross Profit (TTM)2.18B
EBITDA913.30M
Profit Margin20.91%
Operating Margin22.19%
Return on Equity22.09%
Return on Assets11.70%
Shares Outstanding101.65M
Shares Float100.35M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 29 analystsTarget 206.22
  • Strong Buy
    21
  • Buy
    4
  • Hold
    4

Ownership Breakdown

Institutions
104.46%
Insiders
1.06%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    13.71M13.49%
  • JPMorgan Chase & Co
    6.40M6.29%
  • Dodge & Cox
    5.58M5.49%
  • Vanguard Portfolio Management, LLC
    4.97M4.89%
  • Vanguard Capital Management, LLC
    4.55M4.47%
  • State Street Corp
    4.39M4.31%
  • AQR Capital Management LLC
    3.82M3.76%
  • Renaissance Technologies Corp
    2.34M2.30%
  • Geode Capital Management, LLC
    2.14M2.10%
  • Two Sigma Investments LLC
    2.08M2.04%
  • Vestal Point Capital LP
    1.88M1.85%
  • BNP Paribas Investment Partners SA
    1.49M1.47%
  • Morgan Stanley - Brokerage Accounts
    1.32M1.30%
  • RTW INVESTMENTS, LLC
    1.27M1.25%
  • Northern Trust Corp
    1.26M1.24%

Top Fund Holders

  • Dodge & Cox Stock I
    3.91M3.84%
  • iShares Core S&P Mid-Cap ETF
    3.65M3.59%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.23M3.18%
  • Vanguard Small Cap Index
    2.29M2.25%
  • Vanguard MStar Small Cap Growth Indx Inv
    1.27M1.25%